-
Pension concept stocks continue to be popular, and many stocks such as Yuexin Health have daily limit
Time of Update: 2022-04-15
Several pharmaceutical stocks involving the concept of elderly care have risen sharply today, including Yuexin Health, Dongcheng Pharmaceutical, Dean Diagnostics, Xiangyu Medical, Taiji Group, etc.
The two parties plan to jointly initiate the establishment of Nuokai Dongcheng Nuclear Pharmaceutical Industry Investment fund (limited partnership) with a fund size of 500 million yuan .
-
The pharmaceutical equipment industry is developing rapidly, and the market prospect of tangential flow filtration is optimistic
Time of Update: 2022-04-15
The pharmaceutical equipment industry is developing rapidly, and the market prospect of tangential flow filtration is promising.
Overall, there are relatively few domestic manufacturers with independent research and development capabilities in the domestic tangential flow filtration market, and their brand strength is not as strong as that of foreign-funded enterprises.
-
This pharmaceutical stock hit the daily limit again, gaining 6 boards in 8 days!
Time of Update: 2022-04-15
Affected by this news, from March 2nd to 4th, Sinopharm had the daily limit for three consecutive trading days .
It is worth mentioning that on March 11, affected by the news of the cooperation between China Pharmaceuticals and Pfizer, Changjiang Health and Peking University Pharmaceuticals also increased their daily limit.
-
In 2024, the traditional Chinese medicine market may exceed 1 trillion yuan!
Time of Update: 2022-04-15
At the same time, the investment of traditional Chinese medicine companies in the research and development of new drugs has also continued to increase .
-
Strategy for the second quarter of 2022 in the pharmaceutical field: overall or relatively stable, investment still needs to be carefully selected
Time of Update: 2022-04-15
The agency predicts that according to the performance of Zhaoyan New Drug, the company's net profit in 2022-2023 is expected to be 730 million, 920 million, and 2022-2023 EPS will be 1.
-
Industry: The domestic pharmaceutical equipment industry has ushered in the third opportunity for rapid development
Time of Update: 2022-04-15
Pharmaceutical equipment (photo source: Pharmaceutical Network) In terms of the current domestic biopharmaceutical equipment market scale, data shows that in 2020, China's biopharmaceutical equipment and consumables represented by reactor systems, disposable reaction bags, chromatography equipment, etc.
-
The pharmaceutical rivers and lakes are surging, and a group of local pharmaceutical company executives have returned to multinational pharmaceutical companies!
Time of Update: 2022-04-15
According to the data, Qian Wei has more than 25 years of rich experience in the pharmaceutical industry, and has worked in large multinational pharmaceutical companies such as Eli Lilly, AstraZeneca, and Roche .
-
Opportunities and challenges coexist in the traditional Chinese medicine formula granule industry, how should enterprises respond?
Time of Update: 2022-04-15
In the context of the ever-changing environment in the pharmaceutical industry, the company continues to carry out innovation, transformation and upgrading, strengthen brand and channel construction, increase innovation investment, improve operational quality and efficiency, and stabilize its position in the industry.
-
Since 2022, many pharmaceutical companies have ceased production and no longer operate, and the pharmaceutical market reshuffle has intensified!
Time of Update: 2022-04-15
On January 21, the Gansu Provincial Food and Drug Administration issued an announcement to cancel the "Drug Production License" of 10 pharmaceutical companies .
In addition, in January, the Yunnan Provincial Food and Drug Administration also issued a number of announcements to cancel the "Drug Production License" of the enterprise .
-
Technological innovation is making pharmaceutical equipment companies glow with "new vitality"
Time of Update: 2022-04-15
Technological innovation is bringing "new vitality" to pharmaceutical equipment companies (Source: Pharmaceutical Network) For example, on January 10, Tofflon's 2021 performance pre-increase announcement showed that the expected net profit is 765 million yuan to 9.
-
Pharmaceutical companies have embarked on the road of innovation, and these pain points may become "stumbling blocks"
Time of Update: 2022-04-15
According to the industry, the investment of large pharmaceutical companies in drug innovation has been increasing in recent years, but there are still very few new drugs that can enter the market every year, and the number of failed new drug R&D projects is still increasing day by day .
-
The development of the traditional Chinese medicine formula granule industry has entered a new stage, and the transformation and upgrading of pharmaceutical enterprises is urgent
Time of Update: 2022-04-15
In recent years, with the enhancement of residents' awareness of health care, the continuous release of policy dividends, and the active deployment of a large number of enterprises, the market of traditional Chinese medicine granules has maintained a rapid growth trend .
-
The traditional Chinese medicine sector is active again, and stocks such as Longjin Pharmaceutical have opened their daily limit
Time of Update: 2022-04-15
The third quarterly report shows that in the first three quarters of 2021, the company's main income was 969 million yuan, a year-on-year increase of 4.
Shanghai Kaibao is a comprehensive pharmaceutical company mainly engaged in the R&D, production and sales of modern Chinese medicines .
-
The pharmaceutical industry is pushing for intelligent transformation to improve production efficiency and product quality
Time of Update: 2022-04-15
From the above point of view, through the implementation of intelligent transformation, pharmaceutical companies can achieve cost reduction and efficiency improvement, which has become an important starting point for promoting the high-quality development of the pharmaceutical industry .
-
Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance
Time of Update: 2022-04-15
Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
-
10 boards in 12 days!
Time of Update: 2022-04-15
According to the 2021 third quarter report released by Panlong Pharmaceutical, the company achieved a total operating income of 623 million yuan in the first three quarters of 2021, a year-on-year increase of 37.
-
In 2022, these traditional Chinese medicine subdivisions may break out!
Time of Update: 2022-04-15
The industry believes that the future expansion of the traditional Chinese medicine formula market is expected to accelerate, and the filing system and the new national standard will build high industry barriers .
-
12 pharmaceutical stocks daily limit, belonging to traditional Chinese medicine, pharmaceutical business and other sectors
Time of Update: 2022-04-15
According to the data, Gongtong Pharmaceutical is a company specializing in the research and development, production and sales of steroid drug raw materials.
-
Under the new policy of medical reform, pharmaceutical distribution enterprises have accelerated their transformation!
Time of Update: 2022-04-15
The company has stated that under a clear development strategy, around the goal of improving value to increase market value, standardize operations, adhere to the concept of "performance is king" and further promote enterprise transformation and innovation, continue to optimize business models and profitability, and improve.
-
Under the escort of the policy, the Chinese medicine industry is expected to usher in a new life!
Time of Update: 2022-04-15
Among them, in terms of the traditional Chinese medicine formula granule business, the company continued to strengthen the national production capacity layout, continued to improve the market coverage and the penetration rate of the stock market, and achieved a significant increase in revenue and profit compared with the same period of the previous year .